MarginsXMarginsX
Home › Markets › Health Care › MANE

Veradermics Incorporated (MANE)

MANE trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$128.05
-1.24% on the day
Market cap
$5.4B
Mid cap
Revenue
Recent IPO: no annual report filed yet
Net income
Recent IPO: no annual report filed yet

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerMANE on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2026
SEC CIK0001827635
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

Recent IPO: no annual report filed yet.

Warning signs

Cash runway
19.3 months
$132.2M cash at September 30, 2026
Share count, 1 year
No year-earlier count
Going-concern doubt
No
10-Q filed November 10, 2026
Insider net buying, 12 months
-$68.3M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"In accordance with Accounting Standards Update ( ASU ) 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (Subtopic 205-40) , the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are is"
10-Q 2026-11-10
Cash and burn$132.2M cash; operating cash flow -$20.6M a quarter.Report 2026-09-30
Shares outstanding42,195,472 (2026-11-05).Cover page 2026-11-05
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, Hartford, Connecticut, United StatesPCAOB Form AP 2026-04-14
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $34.8M, sold $103.1M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$21.0M-$22.9M$132.2MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q2 2026
2026-06-30
Not filed-$23.5M-$14.5M$319.3MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q1 2026
2026-03-31
Not filed-$27.2M-$21.2M$168.4MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q4 2025
2025-12-31
Not filed-$21.8M-$23.6M$21.8MNo debt tagsNeeds four quarters10-K 2026-03-30
Q3 2025
2025-09-30
Not filed-$20.1M-$19.0M$5.7MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q2 2025
2025-06-30
Not filed-$15.6M-$15.6M$8.6MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q1 2025
2025-03-31
Not filed-$12.4M-$13.3M$32.4MNo debt tagsNeeds four quarters10-Q 2026-11-10

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-08-14
Latest annual report10-K2026-03-30
Latest quarterly / interim10-Q2026-11-10
Latest current report8-K2026-11-10

Source: SEC EDGAR submissions feed, 104 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-6.6%
1 month+11.5%
3 months+16.8%
Year to dateNot enough price history
1 yearNot enough price history
From 52-week high-17.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ERASErasca Inc.$15.11-3.51%$5.3B
PTCTPTC Therapeutics Inc.$60.97-3.97%$5.1B
LQDALiquidia Corporation$56.37-1.81%$5.1B
DNTHDianthus Therapeutics Inc.$89.55-2.46%$5.0B
MIRMMirum Pharmaceuticals Inc.$91.58-2.56%$6.0B
SUPNSupernus Inc.$28.83-2.99%$6.0B
GRFSGrifols S.A.$8.73+0.46%$6.0B
LGNDLigand Pharmaceuticals Incorporated$301.71-2.29%$6.0B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier